Connect with us


Scientists reveal alternative Alzheimer’s approach in new report

Avatar photo



Scientists have published a new, peer-reviewed article that supports alternative approaches for Alzheimer’s disease – and counteracts claims by “potentially doctored” images. 

The new publication in Molecular Psychiatry comes just weeks after an investigation uncovered possible tampering and the falsification of images which could damage long-held beliefs about the causes of Alzheimer’s – including Genuv’s hypothesis.

But this most recent piece, it is claimed,  provides validation of Genuv’s novel neuro-protection approach to Alzheimer’s and offers a new approach to treating the disease. 

The findings 

The results showed that mice with a human form of Alzheimer’s that were treated with Genuv’s SNR1611 drug candidate were able to preserve existing brain cells.

The mice actually regained neural and cognitive functions that had been lost to the disease, as shown by maze tests and an ability to recognise new objects placed in their environment.

The new research provides important validation for the company’s six-year effort to develop new treatments for neurodegenerative diseases including Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).

Who is Genuv?

Genuv Inc is a Korean, clinical-stage biotechnology company focused on innovative drug discovery for central nervous system disorders. It also specialises in advanced antibody therapies for immuno-oncology.

Founder and CEO Dr Sungho Han commented: “We are excited to share these extremely encouraging preclinical results.

“We believe we have demonstrated early proof of a new approach to neurodegenerative disease, focused on neuro-protection and neurogenesis.

“We plan to continue our pre-clinical exploration of MEK 1/2 inhibitors.”

Dr. Han is a member of the team that conducted the research into SNR1611. All research relevant to the publication was conducted in Genuv’s laboratories or under Genuv’s supervision.

SNR1611 is currently in a Phase 1/2a clinical trial in Korea for ALS.


Previously on Health Tech World:

Alzheimer’s research scandal: sleuths raise alarm on potentially “doctored” images

Continue Reading


  1. Pingback: Data breakthrough: Using CNLP to improve population health

  2. Pingback: Researchers seek non-opioid alternatives to manage neuropathic pain

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories